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Background: The intermediate filament protein nestin is used as a marker for neural stem cells, and its expression
is inversely correlated with cellular differentiation. More recently, nestin expression has also been described in other
cell types including multipotential mesenchymal stromal cells (MSCs). In this study, we examined the expression of
nestin in equine, canine and human bone marrow-derived MSCs undergoing osteogenic differentiation, to determine
whether nestin levels were attenuated as the cells acquired a more mature phenotype. In addition, the expression of
nestin may be under the influence of cellular hypoxia, as nestin expression is known to increase in areas of ischemic
tissue damage. Therefore, we also examined the effects of hypoxia on expression of nestin in human MSCs and
examined a role for hypoxia inducible factor 1-alpha (HIF-1α) and vascular endothelial growth factor (VEGF) in the
response. Additionally, we quantified the temporal expression of nestin in the fracture callus during bone regeneration,
a site that has been characterized as hypoxic.
Results: There were no significant changes in nestin expression in MSCs during osteogenic differentiation. There was a
significant increase in expression of nestin mRNA and protein in human MSCs in response to hypoxia (1% O2) or the
chemical hypoxia mimetic desferroxamine. This may be due to upregulation of VEGF under hypoxia, as treatment of
cells with the VEGF receptor antagonist CPO-P11 attenuated hypoxia-induced nestin expression. A significant increase
in nestin mRNA expression was observed in the fracture callus of mice three and seven days post fracture.
Conclusions: Nestin was not a selective marker for MSCs, as its expression was maintained during osteogenic
differentiation, in all species examined. Furthermore our data suggest that nestin expression can be induced by
hypoxia, and that this increase in nestin is partially regulated by HIF-1α and VEGF. Interestingly, nestin levels were
significantly upregulated at the fracture site. Further studies are required to understand the role of nestin in bone cell
biology and ultimately bone regeneration.
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The multilineage potential of MSCs was first reported
in 1966 by Friedenstein et al. [1]. Subsequently, nu-
merous studies investigated the potential of MSCs to
participate in the repair and regeneration of diseased
and damaged tissue, including bone [2-4]. MSCs mi-
grate to sites of tissue damage by recognizing and res-
ponding to chemokines critical for cell homing [5-8].
Indeed MSCs were shown to improve the biomechanical
properties of regenerated callus in a mouse model [4].
Yet the intricate mechanisms dictating the activation,* Correspondence: awong@ucdavis.edu
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unless otherwise stated.trafficking and beneficial properties of MSCs are still
under investigation.
The isolation and definitive characterization of MSCs
is complex. The number of MSCs found in adult tissue
is relatively low and appears to decrease with age, so that
cell-based therapies will likely rely on the expansion of
MSC populations ex vivo [9]. In order to isolate and ex-
pand such cells to determine their roles in bone or other
tissue regeneration, markers and methodology for distin-
guishing undifferentiated MSCs from a heterogeneous
cell population must be clearly defined. Currently, MSCs
are characterized by their ability to self-renew and un-
dergo tri-lineage differentiation into osteoblasts, adipo-
cytes, and chondrocytes; these cells are further identifiedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 Alkaline phosphatase activity, calcium deposition and
nestin expression during osteogenic differentiation of human
MSCs. A. Representative wells demonstrating the effects of time in
osteogenic media on alkaline phosphatase activity (ALP) and
calcium deposition (Alizarin red staining; AR). B. Effects of time in
osteogenic media on Nestin expression in hMSCs. Bars represent
mean nestin expression normalized to ribosomal protein L13 ± SEM
relative to day 0 (n = 5).
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CD14 or CD11b, CD79alpha or CD19 and further lacking
HLA-DR surface molecules [10,11]. However these re-
quirements may not be conserved between species [12].
Nestin, an intermediate filament, has been identified
as a marker of neural stem cells [13-15]. The expres-
sion of nestin in these cells is inversely correlated with
cellular differentiation and thus it is thought to repre-
sent a developmentally regulated marker of immature
cell status [14]. Increases in the number of nestin-
immunopositive cells have been reported in areas of
the damaged rat brain following cerebral ischemia and
traumatic brain injury [16]. However, nestin expression
may not be limited to neuronal lineage cells and more-
over may represent a common marker for multilineage
progenitor cells [17-19]. Nestin expression has been
demonstrated in human, plastic adherent bone marrow
derived MSCs [18]. Additionally, CD45-/nestin + cells
from bone marrow were able to form colony-forming
unit fibroblasts, and were able to undergo tri-lineage
differentiation [17].
Nestin expression may also be regulated by hypoxia.
The bone marrow niche, which contains nestin-positive
progenitor cells, is hypoxic [20] and nestin expression
increases in cells near areas of ischemic damage in rat
brain [21], kidneys [22] and heart [23]. In this study we
examined the expression of nestin in equine, canine and
human bone marrow derived MSCs undergoing osteo-
genic differentiation to determine whether nestin levels
were attenuated as the cells acquired a more mature
phenotype. We also examined the effects of hypoxia
on expression of nestin in human MSCs and exam-
ined a role for hypoxia inducible factor 1-alpha (HIF-1α)
and vascular endothelial growth factor (VEGF) in the
response. Additionally, we quantified the temporal ex-
pression of nestin in the fracture callus during bone re-
generation, a site that has been characterized as hypoxic
[24-27].Results
Nestin expression is maintained during MSC differentiation
An increase in ALP staining in parallel with positive AR
staining was used as a qualitative evaluation of osteoge-
nic differentiation. Increased ALP and AR staining over
time in osteogenic media confirmed that both human
and canine MSCs differentiated in culture (Figures 1
and 2, respectively). We have previously confirmed os-
teogenic differentiation of equine bone marrow-derived
MSCs under conditions identical to those used here
[28]. There were no significant changes in nestin ex-
pression in MSCs induced to undergo osteogenic diffe-
rentiation, in any species investigated (Figures 1B, 2B
and 3). Nestin mRNA expression was normalized acrosstime points to day 0 expression. Our findings suggest
that nestin expression is not correlated to osteogenic
differentiation state.Hypoxia induced nestin expression in hMSCs
There was a significant increase in nestin mRNA expres-
sion in hMSCs at 24 hours post incubation in 1% O2
compared to cells incubated at 21% O2 (Figure 4A). This
rise in nestin expression was transient, as it was followed
by a significant decrease at 48 hours (Figure 4A). Nestin
protein levels were significantly greater in 1% O2 at both
6 and 24 hrs (Figure 4B). Furthermore, treatment of
hMSCs with desferroxamine, an iron chelator and sta-
bilizer of HIF-1α, increased nestin mRNA expression at
6 and 24 hours, at which time this increase achieved
statistical significance (Figure 4C). Our data suggest that
nestin mRNA and protein levels are increased under
hypoxic conditions via a mechanism requiring the HIF-α
family of transcription factors.



































Figure 2 Alkaline phosphatase activity, calcium deposition and
nestin expression during osteogenic differentiation of canine
MSCs. A. Representative wells demonstrating the effects of time in
osteogenic media on alkaline phosphatase activity (ALP) and
calcium deposition (Alizarin red staining; AR). B. Effects of time in
osteogenic media on Nestin expression in cMSCs. Bars represent
mean nestin expression normalized to β2-microglobulin ± SEM
relative to day 0 (n = 5).































Figure 3 Effects of time in osteogenic media on nestin
expression in equine MSCs. Bars represent mean nestin expression
normalized to PPIB ± SEM relative to day 0 (n = 5).
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with VEGF receptor antagonist
VEGF levels are increased under hypoxia via a mechan-
ism that involves the HIF-α family [29,30]. VEGF in turn
has been shown to control the expression of a number
of genes including annexin A2 [31,32]. We observed a
significant increase in VEGF expression in hMSCs cul-
tured in 1% O2 for 24 hrs when compared to cells cul-
tured at 21% O2 (Figure 5a). Interestingly, treatment of
cells with the VEGF receptor antagonist CPO-P11 at-
tenuated 1% O2−induced nestin expression at 24 hrs
(Figure 5b). Our data suggest that VEGF plays a role in
the mechanism by which nestin expression increases
under hypoxic conditions.
Nestin expression increases over time in the fracture callus
A significant increase in nestin mRNA expression was
observed in the fracture callus of mice three and seven
days post fracture (Figure 6).
Discussion
Nestin is recognized as a marker of neural progenitor
cells, wherein nestin expression is inversely correlated
with cellular differentiation and is thus developmentally
regulated [14,19]. Specifically the transition from prolif-
erating neural stem cell to post-mitotic neurons leads to
the down-regulation of nestin [19,33]. Recent studies
have indicated that nestin is also expressed in a variety
of other cells including cells of mesenchymal phenotype,
hair follicle stem cells [34] and newly proliferating endo-
thelial cells [35], and may be a potential general marker
of immature cell types [18,34-36]. Specifically CD45−
nestin+ cells have been described as MSCs, maintaining
self-renewal and multilineage mesenchymal differenti-
ation potential [17]. However, depending on cell source
nestin expression in mesenchymal-like stem cells can be
variable [37]. In our study nestin was expressed in MSCs
derived from equine, canine and human bone marrow.
Nestin mRNA expression did not significantly change
during osteogenic differentiation. The maintenance of
nestin levels throughout the process of osteogenic differ-
entiation suggests that nestin expression is not exclusive
to undifferentiated MSCs, but is maintained throughout
their osteogenic lineage commitment and differentiation.
The consistency of this finding between between species
suggests that nestin expression is not an effective means
of determining the unspecialized status of MSCs.
Nestin expression levels are increased in tissues with
ischemic damage [21-23]. Increased nestin at sites of is-
chemia could be due to the migration of nestin positive
progenitors to the site, or up-regulation of nestin expres-
sion in resident progenitors or more committed cells in
response to the hypoxic environment. Nestin expression
































































































Figure 4 Hypoxia and HIF-1α stabilization promote Nestin expression in hMSCs. A: qPCR analysis of nestin expression after 6, 24 and 48 hrs
of culture at 21% or 1% O2. Bars represent mean nestin expression normalized to ribosomal protein L13 ± SEM relative to 21% at that same time
point (n = 3). *Indicates p < 0.05. B: Quantification of nestin protein expression in hMSCs cultured in 21% and 1% O2. Bars represent mean protein
expression normalized to tubulin ± SEM relative to 21% at the same time point (n = 2) C: qPCR analysis of Nestin expression after 6, 24 and 48 hrs
of culture at 21% O2 in the presence of 100 μM desferroxamine (DFO), an iron chelator and stabilizer of HIF-1α (n = 3). *Indicates p < 0.05,
**indicates p < 0.01.









































































Figure 5 Inhibition of nestin expression by VEGF receptor antagonist. A. qPCR analysis of VEGF expression in hMSCs cultured at 21% or 1%
O2 for 24 hrs. Bars represent mean VEGF expression normalized to ribosomal protein L13 ± SEM expression relative to 21% O2 (n = 3). B. qPCR
analysis of nestin expression after 24 hrs of culture at 21% and 1% O2 in the presence or absence of 10 μM of CBO-P11, a VEGF receptor antagonist.
Treatment with CBO-P11 prevents the increase in Nestin observed in hypoxic conditions. Bars represent mean nestin expression normalized
to ribosomal protein L13 ± SEM expression relative to 21% O2 control (n = 3). *Indicates p < 0.05.
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Our data show that there was a significant increase in
nestin protein expression in hMSCs as early as 6 h
after exposure to 1% O2 compared to cells incubated
at 21% O2. Hypoxia is known to upregulate genes via
the hypoxia-inducible factor (HIF) transcription path-
way. Under normoxic conditions HIF-1α is hydroxylated
by prolyl hydroxylase-domain proteins (PHDs), ubiquiti-
nated by the von Hippel-Lindau tumor suppressor pro-
tein, and undergoes proteosomal degradation. However,
under hypoxic conditions the activity of PHDs is re-
duced, HIF-1α accumulates and forms a heterodimer
with HIF1-β. The HIF-1 complex translocates to the nu-
cleus and binds to the hypoxia-responsive element (HRE)
on target genes to activate transcription [39,40]. To de-
termine the role of HIF-1α in hypoxia-induced nestin ex-
pression we used DFO. DFO chelates iron, an essentialco-factor for the function of prolyl-hydroxylase domains
(PHDs), which under normoxic conditions leads to sta-
bilization and accumulation of HIF-1α [41,42]. In our
study, DFO increased nestin mRNA expression at 6 hrs
that became significantly increased over control at 24 hrs.
Our data show that nestin levels are increased under hy-
poxic conditions, via a mechanism requiring the HIF-1
family of transcription factors.
Vascular endothelial growth factor (VEGF) plays a
pivotal role in neovascularization; and stimulates angio-
genesis necessary for endochondral ossification [43,44].
VEGF is induced by hypoxia under the control of HIF-1α
[30]. Interestingly, we and others have shown that proteins
such as annexin A2 are upregulated under hypoxic condi-
tions in a process that requires VEGF [31,32]. Specifically
we showed that addition of a VEGF inhibiting antibody or




















Figure 6 Nestin expression increases over time in the fracture
callus. qPCR analysis of nestin expression in the murine
fracture callus. Bars represent mean expression ± SEM (n = 3).
*Indicates p < 0.05. **Indicates p < 0.01.
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nexin A2. In this study, as expected, we observed a signifi-
cant increase in VEGF expression in hMSCs cultured in
1% O2, and treatment of cells with CBO-P11 attenuated
hypoxia-induced nestin expression. This suggests that
VEGF plays a significant role in the mechanism by which
nestin expression increases under hypoxic conditions.
Areas of bone damage, such as fracture are hypoxic in
nature due to disruption of the vasculature find [24-27].
MSCs are known to home to, and proliferate in areas of
tissue injury and play a distinctive role in the healing
process including neovascularization and formation of a
fracture callus [45,46]. Thus it is likely that the arrival of
nestin expressing MSCs, and/or the hypoxic nature of the
fracture site might result in increased nestin levels during
bone healing. Our study demonstrated a significant in-
crease in nestin mRNA expression in a callus at days three
and seven days post femoral fracture in the mouse. The
role of nestin during bone healing is not known. A de-
crease in nestin expression has been shown as an essential
prerequisite for the induction of Cdk5-dependant apop-
tosis in neural progenitor cells [47]. Nestin was also shown
to play a protective role against high glucose induced
apoptosis in murine podocytes [48]. The central role of
nestin may therefore be to protect cells from apoptosis in
a hypoxic environment and maintain cellular proliferative
status in areas of tissue injury.
Conclusion
In summary, nestin was expressed in undifferentiated
MSCs of human, canine and equine origin. Furthermore,contrary to our hypothesis that nestin is a marker of un-
differentiated MSCs, nestin expression was maintained
throughout their lineage commitment and osteogenic
differentiation. Our data also show that nestin expres-
sion is significantly upregulated by hypoxia and that this
increase in nestin is in part regulated by HIF-1α and
VEGF. Interestingly nestin levels were significantly up-
regulated at the fracture site, an environment rendered
hypoxic by disruption of blood vessels. Further studies
are required to understand the role of nestin in bone cell
biology and ultimately bone regeneration.
Methods
Cell culture
Canine MSCs (cMSCs) were isolated from bone marrow
as described [49]. Equine MSCs (eMSCs) were derived
from bone marrow isolated from Quarter horses as de-
scribed [28]. Bone marrow was acquired with the approval
from the Institutional Animal Care and Use Committee of
University of California, Davis, USA. Briefly, equal volume
of HBSS was added to the bone marrow aspirate and cen-
trifuged for 15 min at 300 × g. After removing the su-
pernatant, the pellet was re-suspended in HBSS and
centrifuged once more for 5 min at 1000 × g. The pellet
was then re-suspended in media and plated. Adult hu-
man bone marrow-derived MSCs (hMSCs) were pur-
chased from Lonza and used as approved by the UC
Davis Institutional Biological Committee (880-02B). Cells
were seeded at 5,000 cells/cm2 in growth media (RPMI for
cMSCs and eMSCs, and α-MEM for hMSCs), supple-
mented with 10% fetal bovine serum, and 1% penicillin-
streptomycin) and incubated in a standard humidified
incubator (HERAcell 150, Thermo Fisher, USA) at 21%
O2, 5% CO2, and 37°C. Growth media was replaced
every 3 days and cultures were passaged upon reaching
70-80% confluence. Canine cells were used from pas-
sages 2 to 4, while equine and human cells were used
from passages 3 to 5.
Osteogenic differentiation
MSCs from canine, human and equine sources were
seeded at 3000 cells/cm2 in 6-well plates in growth me-
dia. Twenty-four hours after seeding, RNA samples were
collected (day 0) and growth media was replaced with
osteogenic media (growth media supplemented with
100 nm dexamethasone, 10 mM β-glycerophosphate
and 50 μg/mL ascorbic acid phosphate). RNA samples
were collected at days 0, 1, 5 and 10 for hMSC and
cMSC studies, while RNA samples for eMSC studies
were collected on days 0, 2, 4, 6 and 8.
Alizarin Red staining
On days 1, 5, and 10, hMSC and cMSCs were washed
with pre-warmed PBS (37°C) and fixed for 15 min with
Table 1 Taqman qPCR targets and assay numbers
Target Assay no. Species
nestin Hs04187831_g1 Human
VEGF Hs00900055_m1 Human
ribosomal protein L13 Hs00744303_s1 Human
nestin Mm00450205_m1 Mouse
beta-actin Mm00607939_s1 Mouse
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washed with water and incubated with 0.5% Alizarin
Red S (AR; Sigma Aldrich) solution for 15 min. The so-
lution was then removed and the cells were washed with
water until the wash water was clear. Plates were al-
lowed to air-dry prior to imaging. Stained samples were
scanned using a Canon flatbed scanner. AR staining of
differentiating eMSCs was previously performed and
described [28].
Alkaline phosphatase staining
On days 1, 5, and 10, hMSC and cMSCs were stained
for alkaline phosphatase (ALP) using a commercially
available kit (Sigma-Aldrich). Briefly, cells were washed
with pre-warmed PBS (37°C) and fixed with citrate-
acetone-formaldehyde solution. After fixing, cells were
washed with water, incubated with alkaline dye mix-
ture for 15 min, washed and air dried. Cells were then
scanned using a Canon flatbed scanner. ALP staining of
differentiating eMSCs was previously performed and
described [28].
Hypoxia studies
Cells were plated at 5,000 cells/cm2 in 12-well plates and
24 h later media was replaced with pre-conditioned me-
dia from each oxygen tension (21% or 1%). For ambient
(21%) oxygen tension, cells were then cultured in a stan-
dard humidified incubator at 37°C with 5% CO2. For 1%
oxygen tension experiments, cells were cultured in humi-
dified incubators at 37°C with 5% CO2 with oxygen ten-
sion reduced to 1% using supplemental nitrogen (Heracell
150, Thermo Fisher USA) for the indicated time. A subset
of cells were treated with 100 uM desferrioxamine (Sigma,
USA), an iron chelator known to stabilize HIF-1α under
normoxic conditions. In addition, nestin expression was
analyzed after treatment with 10 μM vascular endothelial
growth factor (VEGF) inhibitor CBO-P11 (EMD Millipore).Table 2 SYBR green qPCR targets and primers
Target Genbank Species F
nestin XM_547531 Canine T
β2-microglobulin [30] Canine T
nestin XM_001915709 Equine A
PPIB NM_001099761 Equine GRealtime qPCR quantitative real-time PCR (qPCR)
RNA was purified using the RNeasy Mini Kit (Qiagen)
and reverse transcribed using the Quantitect Reverse
Transcription Kit (Qiagen). Mouse fracture samples were
obtained from a previous study [50]. qPCR for mouse and
human samples was performed using the QuantiFast PCR
Master Mix (Qiagen), and TaqMan primer/probes (Life-
Technologies), the assay numbers are listed in Table 1.
PCR products were amplified under the following condi-
tions: 95°C for 3 min, followed by 40 cycles at 95°C for 3 s
and 60°C for 30s. QuantiFast SYBR Green PCR Master
Mix (Qiagen) was used to amplify canine and equine
genes, the primers are listed in Table 2. Amplification was
performed under the following conditions: denaturation at
95°C for 5 min, 40 cycles of denaturation at 95°C for 10 s,
annealing at 60°C for 30s, followed by a melting curve
procedure. Gene expression was normalized to the loading
control (ΔCt) [51], and was further normalized to control
conditions.
Western blot
Cellular lysates were prepared in RIPA buffer (0.1% Triton
X-100, 10 mM Tris, pH 8, 1 mM EDTA, 200 nM Na3VO4)
with HALT protease inhibitors (Pierce). Protein con-
centration was determined using the DC Protein Assay
(Biorad) following the manufacturer’s instructions. Sam-
ples (40 g protein) were run on a 10% SDS gel and trans-
ferred to a nitrocellulose membrane. The membrane was
probed with nestin (1:100; Novus) or tubulin (1:1000; Cell
Signaling) antibody overnight at 4°C, followed by the ap-
propriate HRP-conjugated secondary antibody (1:1,000;
Jackson ImmunoResearch), and developed with enhanced
chemiluminescent substrate (Denville). Densitometric
analysis was performed with the VisionWorks analysis
software (UVP).
Fracture callus
Murine fractures were performed as previously described
[50]. Briefly, transverse closed femoral fractures were cre-
ated in 13- to 14- week old, male C57BL/6 mice, whose fe-
murs had been stabilized with a stainless steel pin prior to
fracture. The contralateral femurs were used as controls.
RNA was isolated from the fracture callus as pre-
viously described [50]. Briefly, the callus was cut from
the femur, flash frozen in liquid nitrogen and processed
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cDNA with Quantitect Reverse Transcriptase Kit and
qPCR performed using the methods described above.
Results were normalized to the loading control to yield
ΔCt, then normalized to the contralateral limb to yield
ΔΔCt [51]. All procedures were approved by the Institu-
tional Animal Care and Use Committee of the University
of California, Davis.
Statistical analysis
Data were presented as means and error bars represent
standard error of the mean. Statistical analysis of means
was performed using one-way and two-way ANOVA. A
probability level of p < 0.05 was considered statistically
significant.
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